These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17939259)

  • 1. Development of vaccines against influenza A virus (H5N1).
    Li WC; Huang YC
    Chang Gung Med J; 2007; 30(4):294-304. PubMed ID: 17939259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress with human H5N1 vaccines: a perspective from industry.
    Palache B; Krause R
    Expert Rev Vaccines; 2009 Apr; 8(4):391-400. PubMed ID: 19348556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
    Keitel WA; Atmar RL
    Curr Opin Pharmacol; 2007 Oct; 7(5):484-90. PubMed ID: 17644429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emulsion-based adjuvants for influenza vaccines.
    Vogel FR; Caillet C; Kusters IC; Haensler J
    Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflunov(®): a prepandemic influenza vaccine.
    Gasparini R; Amicizia D; Lai PL; Panatto D
    Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influenza A/H5N1 virus outbreaks and prepardness to avert flu pandemic].
    Haque A; Lucas B; Hober D
    Ann Biol Clin (Paris); 2007; 65(2):125-33. PubMed ID: 17353166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines in development against avian influenza.
    Cox MM
    Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.
    Jones T
    Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].
    Loulergue P; Launay O
    Med Sci (Paris); 2009; 25(8-9):719-25. PubMed ID: 19765386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing vaccines against pandemic influenza.
    Wood JM
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1953-60. PubMed ID: 11779397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA-based influenza vaccines: evaluating their potential to provide universal protection.
    Choo AY; Broderick KE; Kim JJ; Sardesai NY
    IDrugs; 2010 Oct; 13(10):707-12. PubMed ID: 20878593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations].
    de Jong JC; Osterhaus AD
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2113-5. PubMed ID: 18856026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008.
    Girard M; Palkonyay L; Kieny MP
    Vaccine; 2008 Sep; 26(39):4975-7. PubMed ID: 18514979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.